Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA

BACKGROUND: Trastuzumab in combination with chemotherapy is the standard first-line (1L) treatment for HER2+ metastatic gastric cancer (mGC) in the USA. OBJECTIVE: This study characterizes the real-world treatment patterns, healthcare resource use (HRU), and costs in patients with HER2+ mGC post-1L...

Descripción completa

Detalles Bibliográficos
Autores principales: Barzi, Afsaneh, Lin, Feng, Song, Jinlin, Lam, Clara, Nie, Xiaoyu, Noman, Ahmed, Kwong, Winghan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491560/
https://www.ncbi.nlm.nih.gov/pubmed/37540381
http://dx.doi.org/10.1007/s40801-023-00378-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491560/
https://www.ncbi.nlm.nih.gov/pubmed/37540381
http://dx.doi.org/10.1007/s40801-023-00378-y

Ejemplares similares